Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 10Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Sarcoma 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 11Nasopharyngeal Carcinoma 4Thyroid Neoplasms 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Melanoma 3Endometrial Neoplasms 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lymphoid Interstitial Pneumonia 2Lung Neoplasms 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Breast Neoplasms 2Urologic Neoplasms 1Tongue Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1

Interventions

pembrolizumab 31Nivolumab 11Ipilimumab 6spartalizumab 5cemiplimab 5atezolizumab 5Gemcitabine 4Docetaxel 4durvalumab 3budigalimab 3avelumab 3Oxaliplatin 3Leucovorin 3Irinotecan 3Immune Checkpoint Inhibitors 3Fluorouracil 3Cyclophosphamide 3Cetuximab 3Carboplatin 3130-nm albumin-bound paclitaxel 3obinutuzumab 2lenvatinib 2fludarabine 2epacadostat 2X-Rays 2Paclitaxel 2Immunoglobulin G 2Cisplatin 2Capecitabine 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Immunoglobulin G × Head & Neck × Clear all
NCT05269381 2026-03-12

PNeoVCA

Mayo Clinic

Phase 1/2 Recruiting
132 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04424641 2023-07-25

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Genmab

Phase 1/2 Terminated
48 enrolled 20 charts
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Prostatic Neoplasms, Uterine Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡